Intelligence Feed event · Equity · 2026-10-20

    XBiotech Reports Positive Final Efficacy Results in Phase II TASKIN Study

    Question

    XBiotech Reports Positive Final Efficacy Results in Phase II TASKIN Study

    Direct answer

    XBiotech reported final efficacy data from the Phase II TASKIN trial assessing its anti-IL-1 alpha monoclonal antibody vilamakitug (XB2001 / Natrunix) in combination with standard chemotherapy for patients with refractory metastatic colorectal cancer. The investigator-sponsored study successfully achieved its primary efficacy endpoint, recording a 12-month overall survival rate of 61.3% in the treatment group. The results validate the biological activity of IL-1 alpha neutralization in refractory solid tumor settings and provide clinical data to support prospective registration trial design.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-20
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “XBiotech Reports Positive Final Efficacy Results in Phase II TASKIN Study”, revision 1, evidence through 2026-10-20. https://marketontology.com/market-events/2026-10-20/xbiotech-reports-positive-final-efficacy-results-in-phase-ii-taskin-study-8102ae

    EQUITY
    XBiotech Reports Positive Final Efficacy Results in Phase II TASKIN Study
    XBiotech reported final efficacy data from the Phase II TASKIN trial assessing its anti-IL-1 alpha monoclonal antibody vilamakitug (XB2001 / Natrunix) in combination with standard chemotherapy for patients with refractory metastatic colorectal cancer. The investigator-sponsored study successfully achieved its primary efficacy endpoint, recording a 12-month overall survival rate of 61.3% in the treatment group. The results validate the biological activity of IL-1 alpha neutralization in refractory solid tumor settings and provide clinical data to support prospective registration trial design.
    XBIT
    Impact
    68
    OCT 20
    SIG
    75%
    XBIT
    XBiotech Reports Positive Final Efficacy Results in Phase II TASKIN Study
    XBiotech reported final efficacy data from the Phase II TASKIN trial assessing its anti-IL-1 alpha monoclonal antibody vilamakitug (XB2001 / Natrunix) in combination with standard chemotherapy for patients with refractory metastatic colorectal cancer. The investigator-sponsored study successfully achieved its primary efficacy endpoint, recording a 12-month overall survival rate of 61.3% in the treatment group. The results validate the biological activity of IL-1 alpha neutralization in refractory solid tumor settings and provide clinical data to support prospective registration trial design.
    → Positive final efficacy results may reduce clinical-development uncertainty around vilamakitug.
    Impact
    XBiotech reported final efficacy data from the Phase II TASKIN trial assessing its anti-IL-1 alpha monoclonal antibody vilamakitug (XB2001 / Natrunix) in combination with standard chemotherapy for patients with refractory metastatic colorectal cancer. The investigator-sponsored study successfully achieved its primary efficacy endpoint, recording a 12-month overall survival rate of 61.3% in the treatment group. The results validate the biological activity of IL-1 alpha neutralization in refractory solid tumor settings and provide clinical data to support prospective registration trial design.
    Affected
    XBIT
    Transmission
    Positive final efficacy results may reduce clinical-development uncertainty around vilamakitug.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    XBITclinical pipeline derisking in oncology indicationUp1-5dXBiotech reported 61.3% 12-month overall survival meeting primary endpoint in Phase II TASKIN trial.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month